

Kartik Sehgal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9284289/publications.pdf>

Version: 2024-02-01

39
papers

6,190
citations

758635

12
h-index

476904

29
g-index

40
all docs

40
docs citations

40
times ranked

11313
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonâ€small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e379-e389.	1.1	13
2	Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with <i>EGFR</i>-G719A and Other Uncommon <i>EGFR</i> Mutations. <i>Oncologist</i> , 2021, 26, 281-287.	1.9	15
3	Targeting the mutant p53 secretome. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	7
4	Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	35
5	Association of Performance Status With Survival in Patients With Advanced Nonâ€Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. <i>JAMA Network Open</i> , 2021, 4, e2037120.	2.8	73
6	Post-acute COVID-19 syndrome. <i>Nature Medicine</i> , 2021, 27, 601-615.	15.2	3,051
7	Hyperprogression in Patients With Cancer Receiving Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2021, 4, e211839.	2.8	12
8	Progressive Multifocal Leukoencephalopathy After Chimeric Antigen Receptor T-Cell Therapy for Recurrent Non-Hodgkin Lymphoma. <i>Journal of Hematology (Brossard, Quebec)</i> , 2021, 10, 212-216.	0.4	2
9	Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?. <i>Frontiers in Oncology</i> , 2020, 10, 1193.	1.3	13
10	Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?. <i>Precision Cancer Medicine</i> , 2020, 3, 17-17.	1.8	14
11	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206
12	Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?. , 2020, 8, e000697.		31
13	Extrapulmonary manifestations of COVID-19. <i>Nature Medicine</i> , 2020, 26, 1017-1032.	15.2	2,300
14	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100074.	0.6	10
15	Effect of performance status on survival with pembrolizumab monotherapy in advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9533-9533.	0.8	1
16	Comparison of outcomes with pembrolizumab monotherapy (P) versus combination with chemotherapy (P+C) in advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e21579-e21579.	0.8	0
17	Association between immune-related adverse events and clinical outcomes to PD-1/PD-L1 blockade in small cell lung cancer. <i>JTO Clinical and Research Reports</i> , 2020, , 100092.	0.6	1
18	248â€...Immunotherapy persister cells uncovered by dynamic single-cell RNA-sequencing. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
19	Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, e1-e3.	0.5	8
20	Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naïve Programmed Death Ligand 1 Positive Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, e34-e36.	0.5	1
21	OA03.07 Immune-Related Adverse Events and Clinical Outcome to Anti PD-1 Axis Inhibition in SCLC: A Multicenter Retrospective Analysis. <i>Journal of Thoracic Oncology</i> , 2019, 14, S213-S214.	0.5	2
22	P2.04-60 Pembrolizumab-Based Regimens Administered at Non-Standard Frequency in Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2019, 14, S731.	0.5	0
23	P1.04-73 Small Cell Transformation of Non-Small Cell Lung Cancer (NSCLC) on Immune Checkpoint Inhibitors: Case Report and Literature Review. <i>Journal of Thoracic Oncology</i> , 2019, 14, S470-S471.	0.5	1
24	Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, 715-722.	1.3	5
25	Clonal Selection Drives NF- κ B Activation in Recurrent Nasopharyngeal Carcinoma. <i>Cancer Research</i> , 2019, 79, 5915-5916.	0.4	1
26	PD-1 antibody pembrolizumab administered at non-standard frequency in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e20617-e20617.	0.8	0
27	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1037-1042.	0.5	83
28	Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors. <i>Translational Cancer Research</i> , 2018, 7, S779-S786.	0.4	43
29	Optimization of immune-related adverse event management in a thoracic oncology clinic.. <i>Journal of Clinical Oncology</i> , 2018, 36, 261-261.	0.8	0
30	Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. <i>Blood</i> , 2015, 125, 4042-4051.	0.6	103
31	Abstract 1354: Comparison of pomalidomide dosing strategies in lenalidomide-refractory myeloma: Impact on clinical outcome, immune activation and cereblon targets. , 2015, ,		0
32	Nanoparticle-Mediated Combinatorial Targeting of Multiple Human Dendritic Cell (DC) Subsets Leads to Enhanced T Cell Activation via IL-15 Dependent DC Crosstalk. <i>Journal of Immunology</i> , 2014, 193, 2297-2305.	0.4	39
33	Targeting human dendritic cells in situ to improve vaccines. <i>Immunology Letters</i> , 2014, 162, 59-67.	1.1	88
34	Plasmacytoid Dendritic Cells, Interferon Signaling, and Fc γ R Contribute to Pathogenesis and Therapeutic Response in Childhood Immune Thrombocytopenia. <i>Science Translational Medicine</i> , 2013, 5, 193ra89.	5.8	26
35	Comparison Of Intermittent and Continuous Dosing Regimens Of Pomalidomide In Relapsed/Refractory Myeloma: Results Of A Phase II Randomized Trial. <i>Blood</i> , 2013, 122, 3205-3205.	0.6	0
36	Enrichment Of Embryonal Stem Cell Signature and Persistent Genomic Complexity In Residual Disease Following Pomalidomide Therapy In Myeloma. <i>Blood</i> , 2013, 122, 4200-4200.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Both Intermittent and Continuous Dosing Regimens Of Pomalidomide Mediate Broad Activation Of Innate and Adaptive Immunity In Relapsed/Refractory Myeloma: Results Of A Phase II Randomized Trial. Blood, 2013, 122, 1949-1949.	0.6	1
38	Development of a Novel in Vivo Model for Human Myeloma Via Humanization of the Bone Marrow Niche. Blood, 2012, 120, 325-325.	0.6	0
39	Development of Hepatic Pseudotumors for Image-guided Interventional and Surgical Research in a Large Animal Model. Journal of Vascular and Interventional Radiology, 2011, 22, 1452-1456.	0.2	4